@fankams99's Ozempic warning claims, fact-checked
Quick answer
GLP-1 receptor agonists like semaglutide work by mimicking hormones that regulate blood sugar and slow gastric emptying. Clinical trials show 14.9% average weight loss at 68 weeks with 2.4mg semaglutide. Most side effects are gastrointestinal and occur during the initial dose escalation period.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What does this TikTok creator actually claim?
@fankams99 warns followers about Ozempic's dangers, listing five major risks: thyroid tumors/cancer, pancreatitis, kidney injury, vision problems, and muscle loss. The creator frames these as reasons to avoid the medication entirely.
The video targets young people concerned about celebrity weight loss trends. It presents these risks as definitive dangers rather than documented side effects with specific frequencies.
Does the science back up these warnings?
The listed side effects are real, but the creator doesn't mention how often they actually occur. The SUSTAIN trials (Marso et al., NEJM, 2016) found thyroid C-cell tumors in animal studies, but no confirmed cases in humans during clinical trials.
Pancreatitis occurred in 0.2% of semaglutide patients versus 0.1% on placebo in the STEP trials (Wilding et al., NEJM, 2021). That's a small absolute increase. Kidney problems typically happened only when patients became severely dehydrated from nausea and vomiting.
The vision claim refers to non-arteritic anterior ischemic optic neuropathy (NAION). A recent study (Hathaway et al., JAMA Ophthalmology, 2024) found higher NAION rates in diabetic patients taking semaglutide, but the absolute risk remains low.
What did the creator get wrong?
The biggest problem is presenting these as common, inevitable outcomes rather than rare side effects. Saying "here are some dangers" without context makes a 0.2% pancreatitis risk sound like a coin flip.
The muscle loss claim is particularly misleading. The STEP 1 trial showed patients lost about 39% of their weight from lean mass, which is actually better than typical diet-only weight loss where 25-30% comes from muscle.
@fankams99 also ignores that most of these risks apply specifically to people with diabetes or other medical conditions, not healthy individuals using the drug off-label.
What should you know about GLP-1 medication risks?
These medications do carry real risks, but they're generally rare and manageable. The most common side effects are gastrointestinal: nausea (44% of patients), diarrhea (30%), and vomiting (24%) in STEP trials.
Serious complications like pancreatitis happen in fewer than 1 in 500 patients. Kidney problems are usually preventable by staying hydrated during initial side effects.
The muscle loss concern is valid but overstated. Resistance training and adequate protein intake can help preserve muscle mass during weight loss, regardless of method.
Should this change how you think about Ozempic?
@fankams99's heart is in the right place, but the fear-mongering approach doesn't help anyone make informed decisions. These medications aren't candy, but they're not poison either.
The real issue isn't the drug's safety profile, which is well-established. It's people using prescription medications without proper medical supervision or understanding of the risks and benefits.
If you're considering GLP-1 medications, focus on whether you're a good candidate and whether you can commit to lifestyle changes that make the treatment effective long-term.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @fankams99's Ozempic warning claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Claim verdict
The useful answer behind this video
Claim being checked
GLP-1 receptor agonists like semaglutide work by mimicking hormones that regulate blood sugar and slow gastric emptying.
FormBlends verdict
GLP-1 receptor agonists like semaglutide work by mimicking hormones that regulate blood sugar and slow gastric emptying. Clinical trials show 14.9% average weight loss at 68 weeks with 2.4mg semaglutide. Most side effects are gastrointestinal and occur during the initial dose escalation period.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- GLP-1 receptor agonists like semaglutide work by mimicking hormones that regulate blood sugar and slow gastric emptying. Clinical trials show 14.9% average weight loss at 68 weeks with 2.4mg semaglutide. Most side effects are gastrointestinal and occur during the initial dose escalation period.
- Pancreatitis occurs in 0.2% of semaglutide patients versus 0.1% on placebo according to STEP trials
- Thyroid tumors appeared in animal studies but no confirmed human cases occurred during clinical trials
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- Pancreatitis occurs in 0.2% of semaglutide patients versus 0.1% on placebo according to STEP trials
- Thyroid tumors appeared in animal studies but no confirmed human cases occurred during clinical trials
- Most side effects are gastrointestinal: 44% experience nausea, 30% have diarrhea
- Muscle loss with semaglutide is actually less than typical diet-only weight loss programs
- NAION vision problems may be increased in diabetic patients but absolute risk remains very low
- Kidney problems typically only occur with severe dehydration from untreated nausea/vomiting
- Serious complications affect fewer than 1 in 500 patients in clinical trials
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
fanKams · TikTok creator
16.7K views on this video
Idols lately been losing weight in a very concerning way, so I Wanted to remind every young girl (or boy) that this is not healthy at all, here are some dangers of the Ozempic medication: 1/Thyroid t
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by fanKams, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.